SARS-CoV-2 Vaccination
5
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Elasomeran
Research Leaders
13 sponsors active, led by ZonMw: The Netherlands Organisation for Health Research and Development
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Adaptive Immune Response to COVID-19 Vaccination
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.
Platelet and Immune Response in Covid-19 Vaccine
Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination
Research Network
Common Treatments
- Elasomeran1
- Immunoassay By Eclia For The Quantitative In Vitro Determination Of Antibodies Including Igg To The Sars Cov 2 Spike Protein S Antirbd Receptorbinding Domain In Serum And Plasma Samples1
- Coronattest1
- Tozinameran1
- Azd 12221
Active Sponsors
- ZonMw: The Netherlands Organisation for Health Research and Development1
- Sanquin Research & Blood Bank Divisions1
- Stefania Basili1
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology1
- UMC Utrecht1
Top Investigators
UMC Utrecht
University of Roma La Sapienza
University Medicine Greifswald, Dept. of Immunology
National Research Center for Hematology
University of Roma La Sapienza
Related Conditions
- Liver Transplantation1
- Sarscov2 Infection1
- Down Syndrome1